Articles

Research suggests that, when used in routine clinical practice in first or subsequent lines of treatment, ribociclib and palbociclib resulted in toxicity and efficacy outcomes in agreement with pivotal trial expectations. Read More ›

A recently released MYLUNG study found that most patients with untreated metastatic NSCLC tested for ≥1 biomarkers, but <50% of patients had ≥5 biomarker tests. Read More ›

Recently released clinical trial results evaluating the effect of early integration of interdisciplinary supportive care found improvement in quality of life, mood, and nutritional status in patients with NSCLC. Read More ›

Caregivers and patients report better understanding of precision medicine and reduced patient anxiety with implementation of a therapeutic patient education program. Read More ›

Study results reveal that KRAS G12C mutations vary according to sex and ethnicity in patients with cancer. Read More ›

For this supplement, the expert faculty provided detailed perspectives based on their extensive experience with the management of cancer patients with bone involvement, especially skeletal-related events associated with solid tumor metastases and lytic lesions due to multiple myeloma. Read More ›

Nivolumab plus chemotherapy in patients with advanced gastric cancer, esophageal adenocarcinoma, or gastroesophageal junction cancer led to significantly higher health-related quality-of-life scores than in patients receiving chemotherapy alone. Read More ›

KEYNOTE-590 study results demonstrate improved overall survival and progression-free survival across subgroups for treatment-naïve patients with advanced esophageal cancer receiving pembrolizumab combined with chemotherapy. Read More ›

Patients with previously treated advanced or metastatic gastric cancer receiving sintilimab showed a modest response rate and an acceptable safety profile. Read More ›

Recently released clinical trial results show that bavituximab in combination with pembrolizumab had promising antitumor activity and was well-tolerated in patients with advanced gastric or gastroesophageal cancer. Read More ›